Michael L. Wolden
Soborg, 2860, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
A time trade-off study in the UK, Canada and the US to estimate utilities associated with the treatment of haemophilia.
Journal: Health and quality of life outcomes
Published: June 14, 2024
Atherosclerotic Cardiovascular Disease in Type 2 Diabetes: A Retrospective, Observational Study of Economic and Clinical Burden in Sweden.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: March 03, 2023
Economic burden of atherosclerotic cardiovascular disease: a matched case-control study in more than 450,000 Swedish individuals.
Journal: BMC cardiovascular disorders
Published: November 23, 2022
Nationwide cardiovascular risk categorization: applying the European Society of Cardiology guidelines to the Swedish National Diabetes Register.
Journal: European journal of preventive cardiology
Published: September 27, 2022
Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study.
Journal: Diabetes, obesity & metabolism
Published: April 19, 2021
Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: November 18, 2020
Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs).
Journal: BMJ open diabetes research & care
Published: August 17, 2020
Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy.
Journal: Journal of medical economics
Published: September 19, 2019
Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study.
Journal: The Journal of clinical endocrinology and metabolism
Published: May 01, 2019
Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non-interventional study (EU-TREAT).
Journal: Diabetic medicine : a journal of the British Diabetic Association
Published: April 16, 2019
Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal-Bolus Therapy.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: January 31, 2019
Last Updated: 09/26/2026